Project Grant R44CA306674
Award Date 9/11/25
Completion Date 8/31/27
Dollars Obligated $1M
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Morrisville, NC, USA
Similar Awards
- The Project Grant award of $1,146,618 was provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Mucommune LLC, a biopharmaceutical company in Morrisville, NC. The grant supports the development of in vivo-engineered CAR-T cells for cellular immunotherapy of pancreatic ductal adenocarcinoma. Specifically, the project aims to leverage Mucommune's proprietary platform that can efficiently transduce non-activated T cells with chimeric antigen receptors (CARs)...
- The National Cancer Institute awarded a $162,486 Project Grant to Northwestern University to develop "tunable microenvironment-responsive CAR T cells using synthetic gene circuits to enhance potency and safety" for the treatment of ovarian cancer. This grant, funded through the Cancer Research Manpower (CFDA 93.398) program, aims to engineer CAR T cells that can specifically target and treat solid tumors, which have posed challenges for current CAR T cell therapies. The project...
- This federal Project Grant award of $222,998.00 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research at the University of California, San Diego (UCSD) to develop a novel virus-like particle (VLP) vector for engineering endogenous immune cells to express chimeric antigen receptors (CARs). The goal is to enable these engineered immune cells, including T cells, NK cells, and macrophages, to mediate potent killing of ovarian cancer cells. This...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy product targeting the MR1 antigen expressed on the surface of various tumor cells, including acute myeloid leukemia (AML) and glioblastoma. The key objectives are to: 1) assess MR1 expression in primary patient AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3)...
- The U.S. National Cancer Institute (NCI) has awarded a $398,997 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to Immunogenik, Inc. to enhance cancer therapeutics with a novel 3-in-1 chimeric antigen receptor (CAR) T cell approach. The research aims to target tumor-associated myeloid cells, which can suppress anti-tumor immune responses, by inhibiting the immunosuppressive LAIR1 signaling pathway. Key deliverables include demonstrating the efficacy of LAIR1...
- This federal Project Grant award of $1,340,987 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to revolutionize chimeric antigen receptor (CAR) T-cell therapy by developing a novel CAR-enhancer platform. The platform seeks to augment the functionality and longevity of CAR T-cells, addressing the key challenge of limited durability of response in patients. The specific objectives of this 24-month project are to: 1) Optimize dosing and timing for administering the...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 in funding to Aerocytek, Inc. to develop an innovative approach for point-of-care autologous CAR-T cell manufacturing. The project aims to overcome current challenges in large-scale production and integration of CAR-T cell therapies by leveraging targeted microbubble-based technologies for T cell selection, activation, and transduction. This solution seeks to democratize the...
- The National Cancer Institute (NCI) awarded Lifengine Animal Health Laboratories Incorporated a $400,000 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395). The award period runs from August 4, 2025 to July 31, 2026. The grant funds the development of chimeric antigen receptor (CAR)-T cell therapies that can overcome functional exhaustion by overexpressing the C-MYB transcription factor. This research aims to improve the therapeutic efficacy and duration of...
- The National Cancer Institute awarded a $176,040 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) from July 1, 2025 to June 30, 2027 under the Cancer Research Manpower (CFDA 93.398) federal grant program. The goal of this project is to develop new strategies to engineer CAR-T cells that can overcome the cancer cell glycocalyx barrier in solid tumors. This will involve: (1) engineering CAR-T cells to strengthen the immune synapse by enhancing binding to the...
- This $195,766 federal Project Grant, awarded on December 19, 2024 by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research at Yale University to develop a mechano-transduction platform for enhancing chimeric antigen receptor (CAR) T-cell therapies for cancer immunotherapy. The key goals are to: 1) measure forces along immune receptors like the T-cell receptor and CAR using force sensors, and 2) engineer force transduction modules that can induce expression of...